Pancreatic Cancer Research

ResearcherUniversity of Colorado Cancer CenterActive in the last 2 years

Todd M. Pitts

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8123-9894; OpenAlex author ID A5073287784. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 7

  1. A Water-Soluble Pro-Drug of Acetaminophen Has Increased Intracellular Delivery of Active Drug and Anti-Cancer Activity in Triple-Negative Breast Cancer and Pan… Co-author DOI 10.3390/cancers18203390↗
  2. Pancreatic Cancer Progression Involves Increased Lysyl Oxidase-Mediated Collagen Cross-Links as Part of the Desmoplastic Reaction. Co-author DOI 10.1021/acs.biochem.5c00125↗
  3. A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection. Co-author DOI 10.1021/acsnano.5c10607↗
  4. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). Last author DOI 10.1371/journal.pone.0298808↗
  5. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Co-author DOI 10.1158/2767-9764.crc-23-0065↗
  6. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.642328↗
  7. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Last author DOI 10.2174/2212697x05666180516120907↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wells A. Messersmith · 5 shared papers, 2018–2025 · strength 0.76
  2. Christopher Hanyoung Lieu · 4 shared papers, 2021–2025 · strength 0.69
  3. Alexis Diane Leal · 3 shared papers, 2021–2024 · strength 0.44
  4. Robert William Lentz · 2 shared papers, 2023–2024 · strength 0.33
  5. Sarah J. Hartman · 2 shared papers, 2021–2024 · strength 0.29
  6. John J. Arcaroli · 2 shared papers, 2018–2024 · strength 0.25
  7. Alex Barrett · 1 shared paper, 2025 · strength 0.25
  8. Komila Rasuleva · 1 shared paper, 2025 · strength 0.25
  9. Alfred Akinlalu · 1 shared paper, 2025 · strength 0.25
  10. Pankaj Kumar Singh · 1 shared paper, 2025 · strength 0.25
  11. Haiyong Han · 1 shared paper, 2025 · strength 0.25
  12. Valerie Marie Weaver · 1 shared paper, 2025 · strength 0.25
  13. Dali Sun · 1 shared paper, 2025 · strength 0.25
  14. Kirk Charles Hansen · 1 shared paper, 2025 · strength 0.25
  15. Allyn Bryan · 1 shared paper, 2026 · strength 0.24
  16. Alexander J. Neuwelt · 1 shared paper, 2026 · strength 0.24
  17. Hayley J Hawkins · 1 shared paper, 2024 · strength 0.18
  18. Carlo Marchetti · 1 shared paper, 2023 · strength 0.15
  19. Jesús Amo‐Aparicio · 1 shared paper, 2023 · strength 0.15
  20. Miles Piper · 1 shared paper, 2023 · strength 0.15
  21. Sana D. Karam · 1 shared paper, 2023 · strength 0.15
  22. Sarah Lindsey Davis · 1 shared paper, 2021 · strength 0.12
  23. Thea Kalebic · 1 shared paper, 2018 · strength 0.07
  24. Anna Schreiber · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.